Cryoport, Inc.Corporate Presentation
August 2016
NASDAQ: CYRX
This presentation contains certain forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include statements regarding attempts to
identify new strategic opportunities which may include a strategic transaction, plans
regarding partnering activities, product pricing, financial forecasts. Such statements are
only predictions and the Company's actual results may differ materially from those
anticipated in these forward-looking statements. Factors that may cause such differences
include the risk that the Company may not be able to identify acceptable strategic
opportunities or conclude any strategic transaction which it does identify, the risk that
products that appeared promising in early use do not demonstrate the same utility in
larger-scale uses, the risks associated with the Company's reliance on outside financing to
meet its capital requirements, and the risks associated with the Company's reliance on
collaborative partners for shipping. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted, or quantified. Future events
and actual results could differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and uncertainties to which forward-
looking statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks. These factors and others are more fully
discussed in the Company's periodic reports and other filings with the Securities and
Exchange Commission.
Safe Harbor – Forward Looking Statements
2August 2016
Transporting Life
3
Cryoport delivers comprehensive cryogenic logistics solutions
for the life sciences industry
PACKAGING
CONDITION MONITORING
INFORMATION
TECHNOLOGY
LOGISTICS EXPERTISE
August 2016
Cryoport Express® Shippersvalidated. safe. effective. efficient.
Novel liquid nitrogen dry vapor technologies
(lighter and safer than LN2 and dry ice)
Designed for fragile biologic transport
Stable cryogenic temperature below -212˚F (below the
“glass point”)
10 day “dynamic” holding time without need for
intervention
Internationale air transport association (IATA) certified,
non-hazardous and “green”
SmartPak II™ condition monitoring system which
monitors internal and external temperatures, humidity,
openings, etc.
4August 2016
SmartPak II™ Launch
Real Time Condition Monitoring
– Mapped location
– Temperature Charting
– Graphical Orientation
– Battery condition
– Pressure
– Humidity
5
Advanced Condition Monitoring System, fully integrated with the CryoportalTM to ensure complete and validated Chain-of-Condition
August 2016
6
Cryoportal™ (At the center of our information technology)
“Central nervous system” for Cryoport
• Order Entry/Processing
• Order Tracking/Management
• Inventory Tracking/Management
• Algorithms for real-time alerts and
intervention management
• Integrated with UPS, FedEx and DHL
CryoportalTM
Technology-driven Life Sciences Logistics
August 2016
Global Logistics Expertise for Life Sciences
Irvine, CA
Launched Global Temperature Controlled Logistics Consulting service
Develop customized solutions that address transport, storage, fulfillment and Information
challenges faced by life science companies
“follow the molecule” program consulting & feasibility planning for logistics
Global operations centers in strategic locations with 24/7/365 “live” support
In compliance with regulations for the life sciences logistics space
Enables clients to focus on their key competencies without the concern of complicated
Logistics requirements
7August 2016
End-to-End Solutions
8August 2016
Recent Strategic Partnerships
Global diversified metals
manufacturing company (NYSE:
WOR) with significant cryogenic
equipment manufacturing expertise
Manufactures Cryoport’s cryogenic
dewars and logistics equipment –
enables cryoport to rapidly scale to
meet client demand
9
Advanced storage and fulfillment
capabilities
Transportation of valuable, and
often irreplaceable, temperature-
sensitive biologic material
Four facilities in the United States
Enables Cryoport to offer
important elements to complete
logistics solutions
August 2016
Cryoport TARGET MarketS
(2016)
10
Regenerative Therapy Logistics Market ($1.16B)**
Clinical Trial Cold-Chain Logistics Market ($3B)*
Pharmaceutical Cold-Chain Logistics Market ($12.6B)*
Total Pharmaceutical Logistics Market ($78.8B)*
*Source: Pharmaceutical Commerce Article, March 15, 2016
**Source: Clinicaltrials.gov Database of Regenerative Therapy Companies
August 2016
Cryoport REGEN MEDICINE Market - 2016
11
*Source: Pharmaceutical Commerce Article, March 15, 2016
**Source: Nature Reviews 2013; (12) 186
$3B Clinical Trial Cold Chain Logistics Market
(2-8°C to -196°C)*
Cryoport Packaging
Opportunity is $400M
Cryoport Logistics
Opportunity is $760M
Total Bio-Storage Market is $23.9B
Regenerative Therapy Bio-
Storage Market $1.41B**Bio-Storage
Logistics Packaging
Informatics
Cryoport
$1.16 B Regenerative Therapy Cold
Chain Logistics Market
(2-8°C to -196°C)*
August 2016
Regenerative Therapy Industry
Snapshot*
12
*Source: Alliance for Regenerative Medicine Quarterly Data Report; Q2, 2016
August 2016
Clinical Trial Progression90 clinical trials – 14 phase III
13
0
10
20
30
40
50
60
70
80
90
100
2001 2002 2003 2004 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Clinical Trials Supported by Year and Cumulative
Series1 Series2
August 2016
14
Top Clinical-stage CAR-T Projects with
Commercial Licensees (excluding China)*
*Evaluate Ltd Juune 2016 “Shifting CAR-Ts Into A Higher Gear” August 2016
Company Academic Centre Project Name
Aurora Baylor College of Medicine AU105
Autolus University College, London IRG-CART
Bellicum Baylor College of Medicine BPX-601
bluebird bio & Celgene Baylor College of Medicine bb2121
bluebird bio Uppsala University CD19 CAR
bluebird bio Baylor College of Medicine CD30 CAR
Cellectis, Pfizer, Servier University College, London UCART19
Cellular Therapeutics Christie Hospital NHS aCD19z
Cellular Therapeutics Cancer Research UK anti-CEA MFEz
Juno Fred Hutchinson & NCI JCAR014
Juno Memorial Sloan Kettering JCAR015
Juno Seattle Children's Hospital JCAR017
Juno via Opus Bio NCI JCAR018
Juno Seattle Children's Hospital JCAR023
Juno Memorial Sloan Kettering JCAR020
Juno Fred Hutchinson JCAR024
Kite Pharma Zelig Eshhar (Cabaret Biotech) KTE-C19
Kite Pharma NCI Anti-EGFRvIII CAR
Leucid Bio King's College London LEU-001
Mustang (Fortress Bio) City of Hope Medical Center MB-102
Mustang (Fortress Bio) City of Hope Medical Center MB-101
Novartis University of Pennsylvania CART-BCMA
Novartis Universtiy of Pennsylvania CTL019
Novartis Universtiy of Pennsylvania CTL119
Novartis University of Pennsylvania CART22 cells
Novartis University of Pennsylvania CART-EGFRvIII
Novartis Universtiy of Pennsylvania CART-meso
Ziopharm, Intrexon, Merck MD Anderson Cancer Center CD19 CAR
August 2016
15
End-to-End Solution
From point of origin to point of destination, Cryoport will provide a fully validated solution, including primary and
secondary packaging, shipping, continuous tracking and monitoring, documentation assistance and 24/7
support.
Steadfast Protection
Navigate cold chain logistics with fully validated Cryoport Express® liquid nitrogen dry vapor shippers that are
being tested and certified after every shipment.
Nonstop Monitoring
Complete visibility and transparency with our CryoportalTM logistics management system and
SmartPak/SmartPak II condition monitoring system. All chain-of-condition and chain-of-custody data for every
single shipment resides in a secure, cloud-based system.
Intelligent Logistics
With over 100,000 cryogenic shipments in and out of over 100 countries, we have unparalleled logistics experience.
Our CryoportalTM, shipping data algorythms and experience enable us to select the best partner from our global
network of integrators, freight forwarders and specialized logistics companies for specific shipping lanes.
24/7 Live Global Support
We provide 24/7 live global support for your complete cold chain logistics needs.
Complete Compliance
Cryoport helps ensure that shipments are in compliance with all applicable regulations. Cryoport’s team of
experts will guide through customs and can manage all documentation.
Risk Mitigation
Our solution is designed to maintain integrity of your materials and data throughout the transit through
purpose built equipment, information technology and proactive monitoring and intervention capabilities by our
experienced cold chain logistics team.
Why Life Science Companies choose Cryoport?
August 2016 15
16
Markets We Serve
Animal HealthReproductive
MedicineBiopharma
August 2016 16
Revenue Trends
17August 2016
18
continuing strong double-digit growth year-over-year and
sequentially…
Q1 FY2017 Revenue Trends(quarter ended June 30, 2016)
+74% +50% +30% +34%
August 2016
SummaryQ1 2017 revenue increased 34% year-over-year
Recently announced first commercial biopharma support
agreement
Supporting 23 of the 28 leading clinical stage CAR-T projects
Over 550 clients; including 28 new biopharma clients in
FYQ1
“powered by cryoport” from FedEx, UPS, and DHL
Cellular therapy market projected to grow to $11.8 billion by
2020
Over 30,000 shipments through 90 countries
Sustainable and growing first-to-market advantage with
growing array of advanced logistics solutions
19August 2016
Board of Directors & Management
Board of Directors
Jerrell Shelton, Chairman of the Board
Richard Berman, Lead Director, Chairman of Audit and Compensation Committees
Robert Hariri, PhD, MD, Director
Ramkumar Mandalam, Ph.D., Director
Edward Zecchini, Chairman of the Nominating and Governance Committee
Management
Jerrell Shelton, CEO
Robert Stefanovich, Chief Financial Officer
Mark W. Sawicki, Ph.D., Chief Commercial Officer
Tamie Joeckel, Senior Vice President Client Services
Bret Bollinger, Vice President Operations
Thomas Heinzen, Vice President Corporate Development
20August 2016
21August 2016
HQ Interior
22August 2016
HQ Interior
23August 2016
HQ Interior
24August 2016
High Volume Shipper
25August 2016
Science. Logistics. Certainty.
NASDAQ: CYRX